As shown in Fig. 4, specific cancer types exhibited a significantly higher prevalence of certain TRAEs when stratified by the utilization of different checkpoint blockade therapies (anti-PD-1, anti-PD-L1, and anti-CTLA-4). This evidence concerns the gene CTLA4 and cancer.